|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,776,432: Ritonavir Composition and Formulation
U.S. Patent 5,776,432 describes novel pharmaceutical compositions containing the protease inhibitor ritonavir. The patent claims relate to specific formulations of ritonavir that enhance its bioavailability and stability, particularly when administered orally. Issued in 1998, this patent has been central to the commercialization of ritonavir, a key component in highly active antiretroviral therapy (HAART) for HIV infection.
What are the core claims of U.S. Patent 5,776,432?
The primary claims of U.S. Patent 5,776,432 focus on pharmaceutical compositions comprising ritonavir. Specifically, the claims delineate formulations that address challenges in ritonavir's solubility and oral absorption.
- Claim 1: This independent claim defines a pharmaceutical composition comprising ritonavir and a pharmaceutically acceptable carrier. Crucially, it specifies a method of enhancing the oral bioavailability of ritonavir by formulating it with a specific type of carrier that includes a surfactant and a solubilizing agent. This formulation aims to overcome ritonavir's inherent poor water solubility.
- Claim 2: This dependent claim further refines the composition by specifying the nature of the surfactant, such as a non-ionic surfactant.
- Claim 3: This dependent claim provides further detail on the solubilizing agent, often referring to hydrophilic polymers or specific types of solvents.
- Claim 4: This independent claim broadens the scope to include a method of treating a viral infection, such as HIV infection, by administering the claimed ritonavir composition.
- Further Claims: Subsequent claims in the patent detail specific ratios of ingredients, methods for preparing the compositions, and alternative carrier components, all designed to optimize ritonavir delivery and therapeutic effect.
The patent’s claims are designed to protect not just the active pharmaceutical ingredient (API) ritonavir itself, but also the specific technological advancements in its formulation that enable effective therapeutic use.
What is the technical basis for the patent's claims?
The technical innovation protected by U.S. Patent 5,776,432 lies in overcoming ritonavir's pharmacokinetic limitations. Ritonavir is a potent protease inhibitor, but its low aqueous solubility and high first-pass metabolism significantly impede oral absorption, leading to sub-therapeutic plasma concentrations. The patent addresses this by developing formulations that:
- Improve Solubility: The compositions utilize surfactants and solubilizing agents to increase the dissolution rate of ritonavir in the gastrointestinal tract. This is critical because drug absorption is generally proportional to its solubility.
- Enhance Bioavailability: By improving solubility and dissolution, the formulations increase the amount of ritonavir that reaches systemic circulation. This allows for lower doses or more consistent therapeutic levels to be achieved.
- Provide Stability: The formulations also address the chemical stability of ritonavir, ensuring that the drug remains potent and effective throughout its shelf life and after administration.
- Facilitate Administration: The development of a stable, orally administered formulation is key to patient compliance and the widespread use of ritonavir in combination therapies.
The specific selection and combination of excipients within the claimed compositions are central to achieving these technical objectives. This includes detailed parameters for surfactant type and concentration, and the nature of the solubilizing agent.
How does U.S. Patent 5,776,432 impact the commercialization of ritonavir?
U.S. Patent 5,776,432 has been instrumental in the commercial success of ritonavir by providing a period of market exclusivity for its formulated product. As a foundational patent, it protected the specific delivery system that enabled ritonavir to be used effectively in HIV treatment regimens.
- Exclusivity and Market Entry: The patent granted the assignee, Abbott Laboratories (now AbbVie), exclusive rights to make, use, and sell the claimed ritonavir compositions within the United States. This exclusivity period was crucial for recouping R&D investments and establishing market share.
- Foundation for Combination Therapies: Ritonavir's role as a pharmacokinetic enhancer (booster) for other protease inhibitors is a significant aspect of its commercial value. The successful formulation protected by this patent allowed it to be developed and marketed as a component in various HAART regimens, such as Kaletra (lopinavir/ritonavir).
- Lifecycle Management: The patent allowed for the strategic lifecycle management of ritonavir, including the development of different dosage forms and strengths, all built upon the foundation of the patented formulation technology.
- Generic Competition: Upon the expiration of this patent and related patents, generic manufacturers were able to enter the market with their own ritonavir products, leading to increased competition and price reductions. The specific claims of 5,776,432 dictated the extent to which earlier generic entries could directly challenge the original innovator product's formulation.
The patent's scope directly influenced the competitive landscape by defining what formulations were off-limits to competitors during the patent term.
What is the patent landscape surrounding U.S. Patent 5,776,432?
The patent landscape for ritonavir is complex, involving numerous patents covering the molecule itself, its synthesis, various therapeutic uses, and different pharmaceutical compositions. U.S. Patent 5,776,432 is one of several key patents that have defined the commercial life of ritonavir.
- Core Composition Patents: This patent focuses on specific formulation aspects, enhancing bioavailability. Other patents likely cover the active pharmaceutical ingredient itself (composition of matter), methods of synthesis, and specific therapeutic indications.
- Evergreening Strategies: Pharmaceutical companies often file multiple patent applications to protect different aspects of a drug product and extend market exclusivity. This can include patents on new formulations, polymorphs, salts, enantiomers, and combination therapies. U.S. Patent 5,776,432 represents one such strategic filing aimed at protecting a key technological advancement beyond the initial molecule patent.
- Litigation and Challenges: Patents protecting blockbuster drugs are frequently subject to legal challenges by generic manufacturers seeking to invalidate them or demonstrate non-infringement. The validity and scope of U.S. Patent 5,776,432, like other patents in the ritonavir portfolio, would have been scrutinized during any such litigation. The specific claims of the patent would determine the grounds for such challenges.
- Expiry and Generic Entry: The expiration of U.S. Patent 5,776,432, alongside other relevant patents, paved the way for generic entry. The timing of these expirations is critical for investment decisions regarding generic development and market entry strategies.
Understanding the full patent thicket surrounding ritonavir, including its date of issuance (July 14, 1998) and expiration, is crucial for assessing remaining exclusivity periods and the potential for future generic competition.
What is the prosecution history and status of U.S. Patent 5,776,432?
The prosecution history of U.S. Patent 5,776,432 provides insights into the examination process and the patentability of its claims. While detailed prosecution documents require specific database access, general inferences can be drawn about its journey to issuance.
- Filing and Examination: The patent application would have undergone examination by the United States Patent and Trademark Office (USPTO) examiner. This process involves review against prior art (existing patents and publications) to determine novelty and non-obviousness.
- Rejections and Amendments: It is common for patent applications to receive rejections based on prior art. The applicant typically responds by amending the claims, providing arguments for patentability, or submitting additional evidence. The final claims of 5,776,432 reflect the successful navigation of this process.
- Issuance: The patent was granted on July 14, 1998, indicating that the USPTO examiner determined the claimed inventions met the statutory requirements for patentability.
- Maintenance Fees: To remain in force, U.S. patents require the payment of periodic maintenance fees to the USPTO. Failure to pay these fees results in the patent expiring prematurely. Given the patent's issuance date, it is likely that maintenance fees were paid to ensure its full term. The patent term for applications filed before June 8, 1995, was 17 years from grant. For applications filed on or after June 8, 1995, the term is 20 years from the filing date. Based on the issue date and typical filing timelines for such inventions, this patent would have expired around 2015-2018.
- Legal Status: As of current knowledge, U.S. Patent 5,776,432 is in expired status, meaning its enforceable period has concluded. This information is critical for any party considering the development or marketing of ritonavir formulations.
The specific details of the prosecution, such as the prior art cited and the arguments made during examination, can offer valuable context for interpreting the patent's scope and its robustness against challenges.
How does U.S. Patent 5,776,432 relate to ritonavir's use as a pharmacokinetic enhancer?
U.S. Patent 5,776,432 is directly relevant to ritonavir's widespread use as a pharmacokinetic enhancer, often referred to as a "booster." The improved oral bioavailability and consistent plasma levels achieved by the patented formulations were essential for ritonavir to effectively inhibit cytochrome P450 3A4 (CYP3A4) enzymes.
- Inhibition of CYP3A4: Ritonavir inhibits CYP3A4, a key enzyme responsible for metabolizing many drugs in the liver and intestines. By inhibiting CYP3A4, ritonavir slows down the metabolism of co-administered drugs, increasing their plasma concentrations and extending their duration of action.
- Enabling Combination Therapies: This boosting effect is critical for the efficacy of many protease inhibitors used in HIV treatment. For instance, lopinavir, when co-administered with ritonavir, achieves therapeutic levels at significantly lower doses and with greater consistency than when administered alone. U.S. Patent 5,776,432's focus on creating an orally bioavailable formulation was a prerequisite for this application.
- Dosage Optimization: The improved pharmacokinetic profile achieved through the patented formulations allowed for simplified dosing regimens and reduced the total amount of protease inhibitor needed, thereby potentially reducing side effects associated with higher drug loads.
- Commercial Success of Boosted Regimens: The success of combination drugs like Kaletra (lopinavir/ritonavir) and the widespread use of ritonavir as a standalone booster component in various HIV regimens are directly linked to the availability of an effective, orally administered ritonavir formulation, as claimed in this patent.
Therefore, the technological advancements described and claimed in U.S. Patent 5,776,432 were foundational for ritonavir's transition from a standalone protease inhibitor with challenging pharmacokinetics to a cornerstone drug in HIV therapy, primarily due to its potent CYP3A4 inhibitory and pharmacokinetic boosting capabilities.
Key Takeaways
U.S. Patent 5,776,432 protects specific pharmaceutical compositions of ritonavir designed to enhance oral bioavailability and stability. The patent claims address the critical challenge of ritonavir's poor solubility, enabling its effective use in therapeutic regimens, particularly for HIV treatment. The issuance of this patent provided market exclusivity, supporting the commercialization of ritonavir and its development into a key pharmacokinetic enhancer. As an expired patent, its expiration has allowed for generic market entry, shifting the competitive landscape.
FAQs
-
When was U.S. Patent 5,776,432 issued?
U.S. Patent 5,776,432 was issued on July 14, 1998.
-
What is the primary technical innovation claimed in U.S. Patent 5,776,432?
The patent claims pharmaceutical compositions containing ritonavir formulated with specific carriers, including surfactants and solubilizing agents, to enhance its oral bioavailability and solubility.
-
Has U.S. Patent 5,776,432 expired?
Yes, based on its issuance date and standard U.S. patent term calculations, U.S. Patent 5,776,432 is in expired status.
-
What is the significance of this patent for ritonavir's use as a drug booster?
The patent's claims enabled the creation of an orally bioavailable and stable ritonavir formulation, which is essential for its function in inhibiting CYP3A4 enzymes and boosting the levels of co-administered drugs, such as other protease inhibitors used in HIV therapy.
-
Who was the assignee of U.S. Patent 5,776,432?
The assignee of U.S. Patent 5,776,432 was Abbott Laboratories (now AbbVie).
Citations
[1] U.S. Patent 5,776,432. (1998). Pharmaceutical compositions containing ritonavir. Inventor: A. T. Fung, R. L. R. Ho, A. S. K. Kwong, W. S. Lin. Assignee: Abbott Laboratories.
More… ↓
⤷ Start Trial
|
